Microwave ablation combined with transarterial chemoembolization containing doxorubicin hydrochloride liposome for treating primary and metastatic liver cancers

Q3 Medicine Journal of Interventional Medicine Pub Date : 2023-08-01 DOI:10.1016/j.jimed.2023.07.002

Qin Shi , Zihan Zhang , Wen Zhang , Jingqin Ma , Minjie Yang , Jianjun Luo , Lingxiao Liu , Zhiping Yan

{"title":"Microwave ablation combined with transarterial chemoembolization containing doxorubicin hydrochloride liposome for treating primary and metastatic liver cancers","authors":"Qin Shi , Zihan Zhang , Wen Zhang , Jingqin Ma , Minjie Yang , Jianjun Luo , Lingxiao Liu , Zhiping Yan","doi":"10.1016/j.jimed.2023.07.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><p>To determine the safety and efficacy of microwave ablation (MWA) and transarterial chemoembolization (TACE) with doxorubicin hydrochloride liposome (DHL) in patients with primary liver cancer (PLC) and metastatic liver cancer (MLC).</p></div><div><h3>Materials and methods</h3><p>The medical records of patients with primary or metastatic liver cancer who underwent MWA combined with TACE containing DHL from March 2019 to March 2022 were collected and analyzed. Treatment-related adverse events (AEs) were recorded. Local tumor response was evaluated according to the modified RECIST criteria. Local tumor progression-free survival (LTPFS) and overall survival (OS) were calculated using the Kaplan-Meier method.</p></div><div><h3>Results</h3><p>Altogether, 96 patients with liver cancer were included (PLC, n = 45; MLC, n = 51). Forty (41.7%) patients experienced AEs during treatment, and eight (8.3%) patients developed grade 3 AEs. Compared to before treatment, the serum total bilirubin level and neutrophil to lymphocyte ratio significantly increased after treatment. The median LTPFS was 14.5 months in patients with PLC and 10.7 months in patients with MLC. The median OS was not reached in patients with PLC or MLC. The 1-month and 3-month disease control rates reached more than 80% in both groups.</p></div><div><h3>Conclusion</h3><p>MWA combined with TACE with DHL may be a safe and effective method for the treatment of liver cancer.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":"6 3","pages":"Pages 121-125"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/34/fe/main.PMC10577058.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Interventional Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2096360223000340","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

To determine the safety and efficacy of microwave ablation (MWA) and transarterial chemoembolization (TACE) with doxorubicin hydrochloride liposome (DHL) in patients with primary liver cancer (PLC) and metastatic liver cancer (MLC).

Materials and methods

The medical records of patients with primary or metastatic liver cancer who underwent MWA combined with TACE containing DHL from March 2019 to March 2022 were collected and analyzed. Treatment-related adverse events (AEs) were recorded. Local tumor response was evaluated according to the modified RECIST criteria. Local tumor progression-free survival (LTPFS) and overall survival (OS) were calculated using the Kaplan-Meier method.

Results

Altogether, 96 patients with liver cancer were included (PLC, n = 45; MLC, n = 51). Forty (41.7%) patients experienced AEs during treatment, and eight (8.3%) patients developed grade 3 AEs. Compared to before treatment, the serum total bilirubin level and neutrophil to lymphocyte ratio significantly increased after treatment. The median LTPFS was 14.5 months in patients with PLC and 10.7 months in patients with MLC. The median OS was not reached in patients with PLC or MLC. The 1-month and 3-month disease control rates reached more than 80% in both groups.

Conclusion

MWA combined with TACE with DHL may be a safe and effective method for the treatment of liver cancer.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

微波消融联合含盐酸阿霉素脂质体的动脉化疗栓塞治疗原发性和转移性肝癌。

目的：探讨微波消融（MWA）和盐酸阿霉素脂质体经动脉化疗栓塞（TACE）治疗原发性肝癌（PLC）和转移性癌症（MLC）的安全性和有效性。材料与方法：收集并分析2019年3月至2022年3月癌症原发性或转移性肝癌患者MWA联合含DHL的TACE治疗的病历资料。记录与治疗相关的不良事件（AE）。根据改良RECIST标准评估局部肿瘤反应。使用Kaplan-Meier方法计算局部肿瘤无进展生存期（LTPFS）和总生存期（OS）。结果：纳入癌症96例（PLC=45；MLC，n=51）。40名（41.7%）患者在治疗期间出现AE，8名（8.3%）患者出现3级AE。与治疗前相比，治疗后血清总胆红素水平和中性粒细胞与淋巴细胞比率显著升高。PLC患者的LTPFS中位数为14.5个月，MLC患者为10.7个月。PLC或MLC患者的OS中位数未达到。两组1个月和3个月的疾病控制率均达到80%以上。结论：MWA联合TACE联合DHL治疗癌症是一种安全有效的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊